To the Editor On behalf of my coauthors, I would like to report an error in our article, “Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial,” published online July 24, 2018, and in the October 2018 issue.1 While working on a separate paper using data from this protocol, we discovered some minor errors in how the analysis of the mean deviations for visual field loss over time were handled. In eTable 6 in Supplement 3, the mean deviation combining the 2 test patterns (Humphrey visual field 30-2 and Humphrey visual field 60-4) was correctly calculated as a weighted average of 2 individual tests by their number of points tested; however, the summary statistics for each individual test should have been reported in their original scale instead of the weighted version as shown in eTable 6. In addition, the mean and standard deviation for the total point score, relative loss, and mean deviation at the 5-year visit should have been calculated with outlying values being truncated at ±3 SD from the mean to minimize the effect of potential outliers. None of the reported P values were affected by these corrections. These errors did not affect the primary results or the conclusions of the article. We regret any confusion this may have caused readers.
Glassman AR. Incorrect Data in Supplement. JAMA Ophthalmol. 2019;137(4):467. doi:10.1001/jamaophthalmol.2019.0001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.